Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy
Language English Country Germany Media print-electronic
Document type Comparative Study, Journal Article
- MeSH
- Acute Disease MeSH
- Dose Fractionation, Radiation * MeSH
- Gastrointestinal Diseases epidemiology etiology MeSH
- Gastrointestinal Tract radiation effects MeSH
- Incidence MeSH
- Combined Modality Therapy MeSH
- Radiotherapy, Conformal adverse effects methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Male Urogenital Diseases epidemiology etiology MeSH
- Prostatic Neoplasms pathology radiotherapy MeSH
- Follow-Up Studies MeSH
- Prospective Studies MeSH
- Prostate radiation effects MeSH
- Cross-Sectional Studies MeSH
- Radiation Injuries epidemiology etiology MeSH
- Radiotherapy, Intensity-Modulated methods MeSH
- Risk Factors MeSH
- Seminal Vesicles radiation effects MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Urogenital System radiation effects MeSH
- Dose-Response Relationship, Radiation MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
PURPOSE: To compare acute and late toxicity after three-dimensional conformal radiotherapy to the prostate to 74 Gy (3D-CRT) with intensity-modulated radiotherapy to 78 Gy (IMRT 78) and IMRT using simultaneous integrated boost to 82 Gy (IMRT/SIB 82). PATIENTS AND METHODS: 94 patients treated with 3D-CRT to the prostate and base of seminal vesicles to 74 Gy represented the first group. The second group consisted of 138 patients subjected to IMRT covering the prostate and base of seminal vesicles to 78 Gy. The last group was treated with IMRT using SIB. The prescribed doses were 82 Gy and 73.8 Gy in 42 fractions to the prostate and seminal vesicles. Late toxicity was prospectively scored according to the RTOG/FC-LENT scale. RESULTS: Acute gastrointestinal toxicity >or= grade 2 occurred in 35.1% of patients treated with 3D-CRT, in 16% subjected to IMRT 78, and in 7.7% receiving IMRT/SIB 82. Acute genitourinary toxicity >or= grade 2 was observed in 26.6% (3D-CRT), 33% (IMRT 78), and 30.7% (IMRT/SIB 82). At 3 years, the estimated cumulative incidence of grade 3 late gastrointestinal toxicity was 14% for 3D-CRT, 5% for IMRT 78, and 2% for IMRT/SIB 82. The difference became significant (log rank p = 0.02). The estimated cumulative incidence of grade 3 late genitourinary toxicity was 9% (3D-CRT), 7% (IMRT 78), and 6% (IMRT/SIB 82) without statistical differences (log rank p = 0.32) CONCLUSION: SIB enables dose escalation up to 82 Gy with a lower rate of gastrointestinal toxicity grade 3 in comparison with 3D-CRT up to 74 Gy.
See more in PubMed
Strahlenther Onkol. 2006 Apr;182(4):240-6 PubMed
Strahlenther Onkol. 2002 Oct;178(10):542-7 PubMed
Strahlenther Onkol. 2006 Sep;182(9):543-9 PubMed
Strahlenther Onkol. 2005 Mar;181(3):172-8 PubMed
JAMA. 2005 Sep 14;294(10):1233-9 PubMed
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 PubMed
Strahlenther Onkol. 2004 Mar;180(3):136-43 PubMed
Semin Radiat Oncol. 2008 Jan;18(1):58-66 PubMed
Strahlenther Onkol. 2007 Jun;183(6):307-13 PubMed
J Urol. 2006 Oct;176(4 Pt 1):1415-9 PubMed
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105 PubMed
Strahlenther Onkol. 2007 Sep;183(9):497-505 PubMed
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):392-8 PubMed
Cancer. 1999 Jun 1;85(11):2460-8 PubMed
Strahlenther Onkol. 2008 Jan;184(1):8-14 PubMed
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):980-8 PubMed
Strahlenther Onkol. 2006 Sep;182(9):537-42 PubMed
Strahlenther Onkol. 2008 Dec;184(12):663-7 PubMed
Neoplasma. 2005;52(2):85-94 PubMed
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):427-35 PubMed
Phys Med. 2005 October - December;21(4):129-35 PubMed
Strahlenther Onkol. 2005 Aug;181(8):483-99 PubMed
Strahlenther Onkol. 2005 Jul;181(7):448-55 PubMed
Semin Radiat Oncol. 2008 Jan;18(1):48-57 PubMed
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):933-9 PubMed
Strahlenther Onkol. 2007 Feb;183(2):57-62 PubMed
Strahlenther Onkol. 2005 Jul;181(7):431-41 PubMed
Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):77-83 PubMed
Strahlenther Onkol. 2000 Jan;176(1):3-8 PubMed
Br J Cancer. 2005 Feb 14;92(3):488-98 PubMed
Int J Clin Oncol. 2008 Feb;13(1):48-53 PubMed
Strahlenther Onkol. 2009 Feb;185(2):94-100 PubMed
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1257-80 PubMed
Strahlenther Onkol. 2008 Dec;184(12):679-85 PubMed
